Budgets Propose Eliminating Interchangeability Status for Biosimilars
-
Apr 11, 2024
When then-President Barack Obama signed the Affordable Care Act (ACA) into law on March 23, 2010, he established the 351(k) biosimilar pathway via the Biologics Price Competition and Innovation Act (BPCIA), which amended the Public Health Service (PHS) Act. Since then, the FDA has approved almost 50 biosimilars, with nearly one fifth of those gaining interchangeable status. That distinction, however, has been increasingly under fire, most recently in President Biden’s fiscal year (FY) 2025 budget, which proposes eliminating the interchangeability designation entirely. That could help boost uptake of biosimilars, resulting in prescription drug savings, say some industry experts.
In contrast to the EU, whose European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) clarified in September 2022 that all biosimilars approved in the EU are interchangeable, the FDA has created two levels of biosimilars: biosimilars and interchangeable biosimilars.
Read more
© 2024 MMIT
Related Posts
-
![]()
Nov 09
FDA Draft Guidance Could Diminish Significance of Interchangeable Biosimilars While Promoting Use of All Biosimilars
Read more -
![]()
Nov 09
Biosimilar Market Has Had Tremendous Year, With No Signs of Slowing
Read more -
![]()
Mar 14
Cardinal Health Report Highlights ‘Pivotal Year’ for Biosimilars
Read more
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.